There are 2137 resources available
744P - Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
Presenter: Petros Grivas
Session: E-Poster Display
Resources:
Abstract
745P - Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)
Presenter: Thomas Powles
Session: E-Poster Display
Resources:
Abstract
746P - EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
Presenter: Peter O'Donnell
Session: E-Poster Display
Resources:
Abstract
747P - Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052
Presenter: Joaquim Bellmunt
Session: E-Poster Display
Resources:
Abstract
748P - Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study
Presenter: Aristotelis Bamias
Session: E-Poster Display
Resources:
Abstract
749P - Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
Presenter: Padmanee Sharma
Session: E-Poster Display
Resources:
Abstract
750P - Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001)
Presenter: Andrea Necchi
Session: E-Poster Display
Resources:
Abstract
751P - Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy
Presenter: Arlene Siefker-Radtke
Session: E-Poster Display
Resources:
Abstract
752P - Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
Presenter: Arlene Siefker-Radtke
Session: E-Poster Display
Resources:
Abstract
753P - Urine tumor DNA methylation assay enables early diagnosis, residual detection and recurrence monitoring for bladder cancer
Presenter: Xu Chen
Session: E-Poster Display
Resources:
Abstract